Abstract:Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer (NSCLC), which is featured by low incidence, high malignancy rate, robust aggressive behavior and inferior prognosis. To date, there is no standardized treatment. The aim of this study is to better understand and accumulate more clinical experience of the disease by summarizing the clinicopathological features, diagnosis methods, therapeutic regimen and prognostic factors of PSC. Methods: A total of 39 patients with PSC who diagnosed and received treatment in Beijing Chest Hospital from December 2013 to December 2023 were retrospectively recruited, and information including demographic characteristics, clinicopathological features, tumor-node-metastasis (TNM) stage, diagnosis method and therapeutic regimen were carefully collected. Meanwhile, follow-up was conducted. Kaplan-Meier method was used to analyze the prognostic factors of the disease. Results: The PSC patients in this study ranged in age from 45 to 76 years old, including 35 males and 4 females. There were no specific clinical manifestations of PSC at initial diagnosis. Among the 39 patients, 20 underwent surgical resection and 19 received palliative chemoradiation or symptomatic supportive treatment. The 1-year and 5-year survival rates were 61.90% and 35.20% respectively. Univariate analysis indicated that family history of carcinoma, primary tumor site, TNM stage, lymph node metastasis, distant metastasis, whether or not received surgical resection, surgical method, treatment regimens, tumor tissue programmed cell death ligand 1 (PD-L1) expression ≥1% and mesenchymal-epithelial transition factor (MET) pathway abnormalities were correlated with the overall survival (OS) of patients (P<0.05). In the subsequent multivariate analysis, lymph node metastasis emerged as the only independent prognosticator in predicting inferior OS (P=0.037). Conclusions: PSC is rarely seen in clinical practice and commonly occurs in elder men with smoking history. Tumor tissue PD-L1 expression ≥1% and MET abnormalities may predict inferior prognosis of PSC and lymph node metastasis was determined as the independent prognosticator of PSC. Surgical resection along with adjuvant medical treatment is the cornerstone for early and locally advanced patients, and the clinical utility of molecular targeting therapy and immunotherapy in PSC needs to be further investigated.

Adjuvant chemotherapy is not a decisive factor in improving the overall survival of pulmonary sarcoma: A population-based study

Pulmonary Sarcomatoid Carcinoma: Experience From SEER Database and Shanghai Pulmonary Hospital

Additional Chemotherapy Improves Survival in Stage II–III Pulmonary Sarcomatoid Carcinoma Patients Undergoing Surgery: a Propensity Scoring Matching Analysis

Clinical analysis of 78 pulmonary sarcomatoid carcinomas with surgical treatment

Clinicopathological characteristics and prognostic factors of pulmonary sarcomatoid carcinoma: a large population analysis

Comparison of Clinical Outcomes in Patients with Advanced Pulmonary Sarcomatoid Carcinoma Treated with Immunotherapy-Based Regimen or Chemotherapy: A Study Based on the SEER Database and Multicentric Real-World Settings

Could Adjuvant Chemotherapy Improve Prognosis For Cervical Cancer Patients With Elevated Pretreatment Serum Squamous-Cell Carcinoma Antigen?

Survival Analysis of Non-Small Cell Lung Cancer Patients with Adjuvant Chemotherapy.

Adjuvant Chemotherapy on Survival of Patients with Stage IB Non‑small Cell Lung Cancer: a Comparison Study with Propensity Score Matching

Effect of Histological Subtype on the Efficacy of Perioperative Chemotherapy in Pulmonary Sarcomatoid Carcinoma: a Retrospective Study Based on SEER Population

[Clinicopathological Characteristics and Prognosis Analysis of 39 Patients with Pulmonary Sarcomatoid Carcinoma]

Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study

Chemoradiotherapy is Associated with Improved Survival for Resected Pancreatic Adenosquamous Carcinoma

Impact of Adjuvant Therapy on Survival in Surgically Resected Limited-Stage Small Cell Lung Cancer

Survival Analysis and Prediction Model for Pulmonary Sarcomatoid Carcinoma Based on SEER Database

Adjuvant chemotherapy improves the prognosis of early stage resectable pulmonary large cell carcinoma: analysis of SEER data.

Chemoradiotherapy is Associated with Improved Survival for Resected Pancreatic Adenosquamous Carcinoma: a Retrospective Cohort Study from the SEER Database

Characteristics and Prognostic Analysis of 69 Patients with Pulmonary Sarcomatoid Carcinoma

Treatment Outcomes of Surgery and Chemotherapy for Pulmonary Metastases from Non-Lung Cancers: a Propensity Score-Matched Analysis

Adjuvant Treatment Can Improve Prognosis in Patients with Non-Small Cell Lung Cancer ≤3 Cm after Sublobectomy: a Propensity Score Analysis

Clinicopathological Features and Prognostic Analysis of Metastatic Pulmonary Sarcomatoid Carcinoma: a SEER Analysis.